References:
[1].
Somer,
T. and S.M. Finegold, Vasculitides associated with infections,
immunization, and antimicrobial drugs. Clin Infect Dis, 1995. 20(4): p.
1010-36.
[2].
Kallenberg,
C.G., The role of bacterial infections for the initiation and
exacerbation of systemic vasculitis. Autoimmun Rev, 2004. 3 Suppl 1: p.
S45-7.
[3].
Robson,
J.C., et al., 2022 American College of Rheumatology/European Alliance of
Associations for Rheumatology classification criteria for granulomatosis
with polyangiitis. Ann Rheum Dis, 2022. 81(3): p. 315-320.
[4].
Nakamura,
Y., et al., Granulomatosis with Polyangiitis following COVID-19 in an
Adolescent. Intern Med, 2023. 62(4): p. 589-593.
[5].
Weynand,
M., et al., A case of left foot drop as initial symptom of
granulomatosis with polyangiitis: Triggered by COVID-19 disease? Clin
Case Rep, 2022. 10(10): p. e6418.
[6].
Selvaraj,
V., et al., COVID-19-induced granulomatosis with polyangiitis. BMJ Case
Rep, 2021. 14(3).
[7].
Lind,
E., A. Jameson and E. Kurban, Fulminant granulomatosis with polyangiitis
presenting with diffuse alveolar haemorrhage following COVID-19. BMJ
Case Rep, 2021. 14(6).
[8].
Izci,
D.T., et al., ANCA-associated vasculitis after COVID-19. Rheumatol Int,
2021. 41(8): p. 1523-1529.
[9].
Bryant,
M.C., L.T. Spencer and A. Yalcindag, A case of ANCA-associated
vasculitis in a 16-year-old female following SARS-COV-2 infection and a
systematic review of the literature. Pediatr Rheumatol Online J, 2022.
20(1): p. 65.
[10].
Qurratulain,
Q., A. Ahmed and Q. Jones, Lesson of the month: Severe granulomatosis
with polyangiitis (GPA): a diagnostic challenge during the COVID-19
pandemic. Clin Med (Lond), 2021. 21(1): p. 79-80.
[11].
Bressler,
M.Y., et al., New Onset Granulomatosis with Polyangiitis Associated with
COVID-19. Case Rep Dermatol Med, 2021. 2021: p. 8877292.
[12].
Giles,
T., et al., Life-threatening gastrointestinal haemorrhage requiring
surgical resection caused by SARS-CoV-2 induced ANCA associated
vasculitis: A case report. Int J Surg Case Rep, 2022. 98: p. 107491.
[13].
Mohammad,
A.J., et al., Incidence and survival rates in Wegener’s granulomatosis,
microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis
nodosa. Rheumatology (Oxford), 2009. 48(12): p. 1560-5.
[14].
Jalalzadeh,
M., et al., Antineutrophil Cytoplasmic Antibody-Associated
Glomerulonephritis in a Case of Scleroderma After Recent Diagnosis With
COVID-19. Cureus, 2021. 13(1): p. e12485.
[15].
Lutalo,
P.M. and D.P. D’Cruz, Diagnosis and classification of granulomatosis
with polyangiitis (aka Wegener’s granulomatosis). J Autoimmun, 2014.
48-49: p. 94-8.
[16].
Kawashima,
S., et al., MPO-ANCA-positive Microscopic Polyangiitis Following
COVID-19 Infection. Intern Med, 2022. 61(4): p. 567-570.
[17].
Shoenfeld,
Y., et al., The mosaic of autoimmunity: genetic factors involved in
autoimmune diseases–2008. Isr Med Assoc J, 2008. 10(1): p. 3-7.
[18].
Toussirot,
E. and J. Roudier, Epstein-Barr virus in autoimmune diseases. Best Pract
Res Clin Rheumatol, 2008. 22(5): p. 883-96.
[19].
Gracia-Ramos,
A.E., E. Martin-Nares and G. Hernandez-Molina, New Onset of Autoimmune
Diseases Following COVID-19 Diagnosis. Cells, 2021. 10(12).
[20].
Allena,
N., et al., A Rare Case of SARS-CoV-2-Induced Microscopic Polyangiitis.
Cureus, 2021. 13(5): p. e15259.
[21].
Garlapati,
P. and A. Qurie, Granulomatosis With Polyangiitis. 2023.
[22].
Lee,
L.E., et al., Clinical Significance of Antineutrophil Cytoplasmic
Antibody Positivity in Patients Infected with SARS-CoV-2. J Clin Med,
2022. 11(14).
[23].
Wang,
Y., et al., Cross-reaction of SARS-CoV antigen with autoantibodies in
autoimmune diseases. Cell Mol Immunol, 2004. 1(4): p. 304-7.
[24].
Cartin-Ceba,
R., T. Peikert and U. Specks, Pathogenesis of ANCA-associated
vasculitis. Curr Rheumatol Rep, 2012. 14(6): p. 481-93.